本地专业知识 · 全球交付
本项支持适用对象
For international pharma teams entering India, emerging biotechs preparing commercial activity and compliance leaders coordinating product, channel and state-level requirements.
Pharmaceutical compliance support in India
本地规则，与您的全球模式相衔接。
Eunomia helps pharmaceutical and biotech teams plan India compliance operations, connecting the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) with advertising law, state-level drug-control processes and practical HCP engagement and review workflows.
咨询此项服务
实际挑战：India
India combines central laws and national marketing-practice requirements with state-level administration of drug manufacture, sale and distribution. Companies also need to operationalise detailed controls for promotional claims, HCP interactions, samples, education programmes and annual marketing-expenditure disclosures.
从要求到行动
Eunomia 如何提供帮助
We can map activities to the applicable national framework, identify state-specific licensing or enforcement questions for local legal review, and translate agreed requirements into SOPs, approval routes, evidence standards and monitoring. Support can include promotional materials review coordination, HCP and event workflows, sample controls, reporting checks, training and automation. India-specific legal advice, licensing work or formal local appointments must be separately scoped with appropriately qualified local professionals; this guide does not claim India-based representation.
我们可承接的工作
制药合规：India：支持范围
本地行业准则解读与问题处理
医疗卫生专业人士及患者组织合作事项审查
本地透明度与披露要求
推广和非推广材料审查
市场准入合规评估
专业能力与语言要求评估
服务带来的价值
适用要求（India）融入您的全球流程
明确审查与升级处理的职责
本地支持，无需增加不必要的固定人员
规则：India
合规的决定因素：India…
主要法律和行业自律框架的简要指南。每项摘要均附有下方的官方来源链接。
UCPMP 2024 is a mandatory national code
The Department of Pharmaceuticals describes UCPMP 2024 as mandatory. It establishes ethical standards for pharmaceutical promotion and industry interactions with healthcare practitioners. Complaints are handled through association-level Ethics Committees for Pharma Marketing Practices, with an appeal mechanism at the Department of Pharmaceuticals. The Code is a distinct compliance layer alongside statutory requirements.
Promotion must follow marketing approval and support its claims
UCPMP says a drug must not be promoted before competent-authority marketing approval and that promotion must remain consistent with that approval. Claims should be current, balanced, verifiable and capable of substantiation. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 separately prohibits misleading drug advertisements and advertisements for specified diseases and conditions. Review intended audience, content and channel against the product approval and applicable law.
HCP benefits and hospitality have strict limits
UCPMP prohibits gifts or personal benefits for healthcare practitioners and their family members, as well as pecuniary advantage or benefits in kind to people qualified to prescribe or supply drugs. It also restricts company-funded travel and hospitality, with limited Code conditions for speakers at CME/CPD programmes; monetary grants to HCPs or family members are prohibited. Build documented purpose, approvals, contracts, event controls and escalation into engagement workflows.
CME, CPD and event support need transparent controls
The Code requires well-defined, transparent and verifiable guidelines for industry engagement in CME/CPD and related events. It prohibits events in foreign locations, identifies eligible organiser categories, and requires companies to publish event and expenditure details on their websites. Organisers must disclose participant and speaker selection procedures, funding sources and expenditure; the Code also sets a 1:10 speaker-to-participant ratio for covered in-country events. Confirm the exact event model, organiser and applicable provisions before committing support.
Samples require eligibility, quantity and value controls
Samples may be supplied only to people qualified to prescribe the product, for awareness and experience, and must be recorded and controlled. UCPMP limits sample packs to the prescribed course for no more than three patients and no more than 12 packs per drug per practitioner each year; packs must be marked not for sale and cannot exceed the smallest market pack. The total monetary value of samples should not exceed 2% of domestic sales. The 2025 amendment clarifies sample valuation for annual reporting.
Annual expenditure reporting and state administration
Under the UCPMP text updated on 1 September 2025, the executive head submits an annual marketing-expenditure disclosure within two months after the financial year, through a member association or the Department of Pharmaceuticals portal where the company is not an association member. The prescribed form captures domestic sales, sample value and HCP recipient counts, and education-programme expenditure and event counts. Separately, CDSCO says states primarily regulate manufacture, sale and distribution of drugs, while central authorities handle functions including new-drug approvals, standards and import quality. Map the state footprint and applicable licensing or enforcement touchpoints.
主要参考资料
Department of Pharmaceuticals: UCPMP 2024 and policy circularsUCPMP 2024 consolidated text, updated 1 September 2025Department of Pharmaceuticals: UCPMP portal and implementationCDSCO: central and state regulatory functionsCDSCO: Acts and RulesIndia Code: Drugs and Magic Remedies Act, 1954Press Information Bureau: UCPMP implementation and disclosures
本概述仅供参考，不构成法律意见。具体适用范围和适用方式，应结合相关机构、市场、活动和交易对方予以确认。信息来源核查于 2026 年 9 月。
常见问题解答
制药合规：India常见问题
Is UCPMP 2024 voluntary or mandatory?
The Department of Pharmaceuticals' UCPMP portal describes the 2024 Code as mandatory. It operates alongside applicable statutes and is implemented through pharmaceutical association ethics committees and a Department-level appeal mechanism.
Can a company promote a medicine before it is approved in India?
No. UCPMP says promotion must not begin before the competent authority has granted marketing approval and must remain consistent with that approval.
Can pharmaceutical companies provide gifts or pay for HCP travel?
UCPMP prohibits gifts, personal benefits and monetary grants to HCPs and their family members, and restricts travel and hospitality. The Code contains limited conditions for speakers at CME/CPD programmes, so each arrangement needs review against the full provision.
What UCPMP transparency reporting applies?
The updated Code requires an annual marketing-expenditure disclosure. Its prescribed form includes domestic sales, sample value and HCP recipient counts, and expenditure and event counts for education programmes. The submission route depends on association membership; check the current Department form and any deadline extensions.
Do state-level requirements matter if UCPMP is national?
Yes. UCPMP and central laws form part of the national framework, while CDSCO says states primarily regulate drug manufacture, sale and distribution. Companies should map state licensing and enforcement touchpoints to their operating footprint.
Does Eunomia have an India office or named India-based representative?
This guide does not claim an India office, India-based representative, legal qualification or formal regulatory appointment. Contact Eunomia to agree the scope, expertise and delivery arrangements required; any local legal advice or formal role must be separately confirmed.
请告诉我们您手头的工作。
我们会认真倾听、了解情况，并推荐合适的服务范围，无需承诺，也没有压力。
开始沟通